|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM348296495 |
| 003 |
DE-627 |
| 005 |
20231226035833.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1021/acs.langmuir.2c01734
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1160.xml
|
| 035 |
|
|
|a (DE-627)NLM348296495
|
| 035 |
|
|
|a (NLM)36315404
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yan, Miaomiao
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Development of Drug Carriers with Biocompatibility Based On Human Serum Albumin and β-Cyclodextrin Molecules and Study of Anticancer Activity
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.11.2022
|
| 500 |
|
|
|a Date Revised 20.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Herein, a novel molecule S4, which could form a uniform S4 spherical aggregate in water, was synthesized, and the S4 aggregate was used to load Dox to prepare the S4Dox nanomedicine. The loading efficiency was 80.0 ± 4.5%. The pH response and slow release of Dox were the typical characteristics of the S4@Dox nanomedicine. In vitro experiments showed that cancer cells could successfully phagocytose S4 aggregates and the S4@Dox nanomedicine. The toxicity of S4 aggregates to MCF-7, HepG2, and H22 cells was low, and the S4@Dox nanomedicine had better antitumor activity and specific targeting, especially to the MCF-7 cells. The antitumor activity in vivo and in the tissue section showed that the S4@Dox nanomedicine could significantly reduce Dox toxicity, effectively induce the apoptosis of cancer cells, and effectively inhibit tumor growth, which showed that the nanomedicine had better antitumor activity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Serum Albumin, Human
|2 NLM
|
| 650 |
|
7 |
|a ZIF514RVZR
|2 NLM
|
| 650 |
|
7 |
|a beta-Cyclodextrins
|2 NLM
|
| 700 |
1 |
|
|a Li, Jing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Xiulian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hou, Xinyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ma, Yue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cui, Haoyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Feng, Chuanxing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ma, Liying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wei, Guangcheng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Langmuir : the ACS journal of surfaces and colloids
|d 1992
|g 38(2022), 45 vom: 15. Nov., Seite 13686-13696
|w (DE-627)NLM098181009
|x 1520-5827
|7 nnns
|
| 773 |
1 |
8 |
|g volume:38
|g year:2022
|g number:45
|g day:15
|g month:11
|g pages:13686-13696
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1021/acs.langmuir.2c01734
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_721
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 38
|j 2022
|e 45
|b 15
|c 11
|h 13686-13696
|